VEGFA and hepatocellular carcinoma: Sorafenib was the first treatment approved for HCC [6] and this paved the way for the development of new drugs including multi-targeted TKIs [7,8,9], as well as the vascular endothelial growth factor (VEGF) inhibitor [10].